Literature DB >> 26830060

Effective case/infection ratio of poliomyelitis in vaccinated populations.

G Bencskó1, T Ferenci2.   

Abstract

Recent polio outbreaks in Syria and Ukraine, and isolation of poliovirus from asymptomatic carriers in Israel have raised concerns that polio might endanger Europe. We devised a model to calculate the time needed to detect the first case should the disease be imported into Europe, taking the effect of vaccine coverage - both from inactivated and oral polio vaccines, also considering their differences - on the length of silent transmission into account by deriving an 'effective' case/infection ratio that is applicable for vaccinated populations. Using vaccine coverage data and the newly developed model, the relationship between this ratio and vaccine coverage is derived theoretically and is also numerically determined for European countries. This shows that unnoticed transmission is longer for countries with higher vaccine coverage and a higher proportion of IPV-vaccinated individuals among those vaccinated. Assuming borderline transmission (R = 1·1), the expected time to detect the first case is between 326 days and 512 days in different countries, with the number of infected individuals between 235 and 1439. Imperfect surveillance further increases these numbers, especially the number of infected until detection. While longer silent transmission does not increase the number of clinical diseases, it can make the application of traditional outbreak response methods more complicated, among others.

Entities:  

Keywords:  AFP surveillance; IPV; OPV; case/infection ratio; poliomyelitis; reproduction rate

Mesh:

Substances:

Year:  2016        PMID: 26830060      PMCID: PMC9150609          DOI: 10.1017/S0950268816000078

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  14 in total

1.  When is a disease eradicable? 100 years of lessons learned.

Authors:  B Aylward; K A Hennessey; N Zagaria; J M Olivé; S Cochi
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

2.  Polio emergence in Syria and Israel endangers Europe.

Authors:  Martin Eichner; Stefan O Brockmann
Journal:  Lancet       Date:  2013-11-08       Impact factor: 79.321

Review 3.  Mucosal immunity and poliovirus vaccines: impact on wild poliovirus infection and transmission.

Authors:  Hiromasa Okayasu; Roland W Sutter; Cecil Czerkinsky; Pearay L Ogra
Journal:  Vaccine       Date:  2011-09-05       Impact factor: 3.641

Review 4.  Expert review on poliovirus immunity and transmission.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Konstantin M Chumakov; Neal A Halsey; Tapani Hovi; Philip D Minor; John F Modlin; Peter A Patriarca; Roland W Sutter; Peter F Wright; Steven G F Wassilak; Stephen L Cochi; Jong-Hoon Kim; Kimberly M Thompson
Journal:  Risk Anal       Date:  2012-07-15       Impact factor: 4.000

5.  Field evaluation of vaccine efficacy.

Authors:  W A Orenstein; R H Bernier; T J Dondero; A R Hinman; J S Marks; K J Bart; B Sirotkin
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

6.  Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated?

Authors:  M Eichner; K Dietz
Journal:  Am J Epidemiol       Date:  1996-04-15       Impact factor: 4.897

Review 7.  From emergence to eradication: the epidemiology of poliomyelitis deconstructed.

Authors:  Neal Nathanson; Olen M Kew
Journal:  Am J Epidemiol       Date:  2010-10-26       Impact factor: 4.897

Review 8.  Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge.

Authors:  Thomas R Hird; Nicholas C Grassly
Journal:  PLoS Pathog       Date:  2012-04-19       Impact factor: 6.823

9.  Polio-free certification and lessons learned--South-East Asia region, March 2014.

Authors:  Sunil Bahl; Rakesh Kumar; Nata Menabde; Arun Thapa; Jeffrey McFarland; Virginia Swezy; Rudolph H Tangermann; Hamid S Jafari; Linda Elsner; Steven G F Wassilak; Olen M Kew; Stephen L Cochi
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-10-24       Impact factor: 17.586

10.  An evaluation of the sensitivity of acute flaccid paralysis surveillance for poliovirus infection in Australia.

Authors:  Rochelle E Watkins; P Anthony J Martin; Heath Kelly; Ben Madin; Charles Watson
Journal:  BMC Infect Dis       Date:  2009-09-30       Impact factor: 3.090

View more
  4 in total

1.  Polio and Measles Down the Drain: Environmental Enterovirus Surveillance in the Netherlands, 2005 to 2015.

Authors:  Kimberley S M Benschop; Harrie G van der Avoort; Edin Jusic; Harry Vennema; Rob van Binnendijk; Erwin Duizer
Journal:  Appl Environ Microbiol       Date:  2017-06-16       Impact factor: 4.792

Review 2.  Eradicating polio in Pakistan: an analysis of the challenges and solutions to this security and health issue.

Authors:  Shoaib Fahad Hussain; Peter Boyle; Preeti Patel; Richard Sullivan
Journal:  Global Health       Date:  2016-10-12       Impact factor: 4.185

3.  Persistence of poliovirus types 2 and 3 in waste-impacted water and sediment.

Authors:  Allison Kline; Kara Dean; Alexandra L Kossik; Joanna Ciol Harrison; James D Januch; Nicola K Beck; Nicolette A Zhou; Jeffry H Shirai; David S Boyle; Jade Mitchell; John Scott Meschke
Journal:  PLoS One       Date:  2022-01-26       Impact factor: 3.240

Review 4.  Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication.

Authors:  Kimberly M Thompson; Dominika A Kalkowska
Journal:  Expert Rev Vaccines       Date:  2020-08-01       Impact factor: 5.217

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.